Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity.
Epidermal growth factor receptor (EGFR) inhibitors are associated with unique and dramatic dermatologic side effects. Skin rash is the dose-limiting factor for all EGFR inhibitors and is usually dose related and reversible. Microbiologic stains and cultures from skin rash usually do not show an infectious cause. We report on a patient with known non-small-cell lung cancer who developed Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity.
Grenader
Tal
T
Department of Oncology, Sha'are Zedek Medical Center, Jerusalem, Israel. talgrenader65@hotmail.com
Gipps
Maya
M
Goldberg
Anthony
A
D016470:Bacteremia / Q000209:etiology*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011799:Quinazolines / Q000009:adverse effects*; D012867:Skin / Q000187:drug effects*; D013203:Staphylococcal Infections / Q000209:etiology*
D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors